Generic name | Strength, form | Special Authority criteria | Approval period |
---|---|---|---|
risedronate | 5 mg tablet or 35 mg tablet |
Clinical or radiographically documented fracture due to osteoporosis OR Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg or more of prednisone per day for 90 or more consecutive days |
Indefinite
1 year |
risedronate | 30 mg | Diagnosis of Paget's disease | Indefinite |
Practitioner exemptions